Back to Database
SS-31
FDA ApprovedSS-31 (Elamipretide)
Also known as: Elamipretide, Bendavia
Low-Moderate
Mitochondrial EnergyAnti-Aging
A mitochondria-targeting tetrapeptide that binds to cardiolipin. Optimizes mitochondrial structure and function. FDA-approved for Barth syndrome (Sept 2025).
Benefits
Restores mitochondrial ATP production
Reverses age-related mitochondrial decline
Increases muscle mass and fatigue resistance
Reduces oxidative stress across organs
Cardioprotective properties
Supports kidney and neurological function
Side Effects & Risks
Injection site reactionsmild
Generally well tolerated in trialsmild
Dosing Information
Typical Dose
5-40 mg/day
Administration
Subcutaneous injection
Cycle Length
Variable by condition
Notes
FDA-approved for Barth syndrome. Off-label protocols vary.
Legal Status
FDA Status
FDA-APPROVED for Barth syndrome (Sept 2025)
Availability
Prescription for Barth; research suppliers for other uses
WADA Status
Not currently banned
Evidence
Evidence LevelHigh
FDA-approved for Barth syndrome with full clinical trial data. However, PROGRESS-HF (heart failure) and MMPOWER-3 (mitochondrial myopathy) trials both FAILED primary endpoints. Benefits outside Barth syndrome are unproven in humans.
Works Well In These Stacks
Where to Buy
Available from verified suppliers
MetaVitality Labs Verified4.7
View Supplier SS-31 (Elamipretide) Research Vial
LyophilizedPurity: 99%+
COA Available Third-Party TestedIn Stock
PeptideLab Sciences Verified4.8
View Supplier Elamipretide Research Vial
LyophilizedPurity: 99%+
COA Available Third-Party TestedIn Stock